Compugen (NASDAQ:CGEN) announced its earnings results on Monday. The biotechnology company reported ($0.14) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.03, Morningstar.com reports.
NASDAQ CGEN opened at $3.45 on Tuesday. The stock has a market cap of $177.47 million, a PE ratio of -8.41 and a beta of 2.43. Compugen has a 52-week low of $2.00 and a 52-week high of $4.31.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC boosted its stake in shares of Compugen by 8.2% during the third quarter. Renaissance Technologies LLC now owns 265,100 shares of the biotechnology company’s stock valued at $1,021,000 after purchasing an additional 20,200 shares during the period. Jane Street Group LLC bought a new position in shares of Compugen during the 3rd quarter valued at approximately $128,000. Morgan Stanley grew its position in Compugen by 2.8% in the 3rd quarter. Morgan Stanley now owns 998,173 shares of the biotechnology company’s stock valued at $3,843,000 after acquiring an additional 27,240 shares during the last quarter. Taylor Frigon Capital Management LLC grew its position in Compugen by 17.2% in the 4th quarter. Taylor Frigon Capital Management LLC now owns 690,262 shares of the biotechnology company’s stock valued at $1,498,000 after acquiring an additional 101,212 shares during the last quarter. Finally, Defender Capital LLC. purchased a new stake in shares of Compugen in the 4th quarter worth $630,000. Institutional investors own 25.43% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Compugen (CGEN) Issues Quarterly Earnings Results, Beats Estimates By $0.03 EPS” was first published by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://dakotafinancialnews.com/2019/05/21/compugen-cgen-issues-quarterly-earnings-results-beats-estimates-by-0-03-eps.html.
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.